Setterwalls has assisted the shareholders in connection with the sale of shares in NDA Group

Setterwalls has assisted the shareholders of NDA Group in connection with SSI Strategy’s acquisition of the company.

NDA Group is a consultancy company specialized in regulatory drug & device development, supporting companies with their regulatory, pharmacovigilance, quality and strategic communication challenges across the US and Europe.

SSI Strategy is a consultancy company that helps companies with drug development with core competencies in clinical development and pharmacovigilance, among others. In December 2020, SSI partnered with Amulet Capital Partners, a middle-market private equity investment firm focused exclusively on the healthcare sector.

For more information, please see the press release here.